Loading…
Loading…
NDRA does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NDRA and 80,000+ other tickers.
See exactly how NDRA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NDRA and 80,000+ other tickers.
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed…
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), reported financial results for the quarter ended June 30, 2026, and provided a business update. Second Quarter 2026 and Recent Highlights On June 25, 2026, ENDRA entered into a definitive merger agreement with ASP Isotopes Inc. (NASDAQ: ASPI), Noble Africa LLC (“Noble Africa”) , R.
DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes”, “ASPI” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today released the following letter to shareholders from its Executive Chairman and Chief Executive Officer, Paul Mann. Dear Fellow Shareholder, As we prepare to announce financial results for the second quarter of 2026, I wanted to take this opportunity to update you on the developments taking place at ASP Isotopes Inc. All of our business units are making considerable progress, group revenues are increasing, and three of our business units appear at an inflection point and are expected to make substantial contributions to achieving profitability in the near term: During 1H 2026, our global PET Labs group demonstrated organic revenue growth of over 50% as compared to 1H 2025.
DALLAS & ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or “ASPI”), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or “NDRA”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that RedChip Companies will host an investor webi.
Noble Africa was created to unlock the value of Renergen's Virginia Gas Project through a public company focused on helium and LNG Learn why the Virginia Gas Project is positioned to become one of the world's most strategic helium developments as global supply tightens and demand accelerates DALLAS, TX AND ANN ARBOR, MI / ACCESS Newswire / July 17, 2026 / ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or "ASPI"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or "NDRA"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that RedChip Companies will host an investor webinar featuring Noble Africa, a wholly owned subsidiary of ASP Isotopes and the holding company for Renergen Limited, on Tuesday, July 21, 2026, at 4:15 p.m. ET. The webinar will highlight Noble Africa's proposed merger (the "Proposed Merger" and, together with the related transactions, the "Proposed Transactions") with ENDRA, which, if completed, is expected to result in Noble Africa becoming a Nasdaq-listed public company trading under the ticker symbol "NOBA.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.